Clinical trials: Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"
To investigate the safety and efficacy of long-term treatment with pioglitazone (Actos tablets) in combination with biguanides (for 12 months after the start of pioglitazone tablets treatment) in patients with type 2 diabetes…
- Trial name
- NCT02003014
- Testing
- Pioglitazone
- Volunteers
- 899 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
This study is conducted in Asia. The aim of this observational study is to investigate the clinical safety profile and effectiveness while using SC NovoRapid™ (insulin aspart) in patients with coexisting diabetes and kidney…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Kidney Disease
- Trial name
- NCT00849316
- Testing
- insulin aspart
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulin Glargine "All to Target" Trial
The primary objectives were: To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic…
- Trial name
- NCT00384085
- Testing
- Insulin Glulisine, Insulin Glargine, Premixed Insulin
- Where
- United States
- Volunteers
- 588 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Insulin Resistance - Type A, Insulin Resistance - Type B
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-02 (NCT04221152)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Diabetes Mellitus Type 2
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin.
- Trial name
- NCT00111631
- Testing
- DPP-IV Inhibitor, Metformin
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone
The purpose of this study is to determine whether markers of b-cell function can predict changes in B-cell function over time in patients with type 2 diabetes mellitus (T2DM) randomized to treatment with metformin or…
- Trial name
- NCT00282945
- Testing
- Rosiglitazone, Metformin
- Where
- 2 sites in Israel
- Volunteers
- 29 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Assessment of Gastric Emptying by SHR20004 in Healthy Subjects
The purpose of this study is to investigate the impact of SHR20004 on the pharmacokinetic (PK) characteristics of acetaminophen in healthy subjects.
- Trial name
- NCT06137469
- Testing
- Acetaminophen/SHR20004
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Improved Glycemic Control in Patients With Type 2 Diabetes
A Trial of HR17031 Injection With Hepatic Insufficiency
This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.
- Trial name
- NCT05151705
- Testing
- HR17031 injection
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Weight Loss
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
- Trial name
- NCT07868939
- Testing
- VK2735 Oral
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity, Overweight
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2…
- Trial name
- NCT06643728
- Testing
- Bimagrumab, Tirzepatide
- Where
- 12 sites in United States
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
- Trial name
- NCT00374907
- Testing
- Saxagliptin, Metformin (blinded), Metformin (open-label)
- Where
- 3 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare India (NCT01351922)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 12,000 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
ECC5004 RBA FE Study in Healthy Participants
This study is a Phase 1, open-label, randomized, single dose, fixed sequence, crossover study designed to compare the relative bioavailability of 50 mg ECC5004 current tablet formulation (F1) and 50 mg ECC5004 new tablet…
- Trial name
- NCT06268145
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Eccogene
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an α-glucosidase inhibitor taken three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01263483
- Testing
- Alogliptin and voglibose, Voglibose
- Volunteers
- 230 people
- Sponsor
- Takeda
Type 2 Diabetes
GALLANT 4 Tesaglitazar vs. Glibenclamide
This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (glibenclamide) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone…
- Trial name
- NCT00255541
- Testing
- Tesaglitazar, Glibenclamide
- Where
- 66 sites in Belgium, Hong Kong and 11 more
- Volunteers
- 580 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Diabetes Mellitus, Type 2
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in…
- Trial name
- NCT00325429
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Novartis